Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long COIN Daily ETF vs TG Therapeutics Inc — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.26 (market cap $510.01M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 16× GraniteShares 2x Long COIN Daily ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and TG Therapeutics Inc for 16 Days on average.
| CONL | TGTX | |
|---|---|---|
Market Cap | $510.01M | $8.16B |
Volume | 21,041,836 | 1,735,121 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $59.06 |
52-Week Low | $3.93 | $26.94 |
Typical Hold Time | 15 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONL, a leveraged ETF tracking COIN, trades at $5.26, up 0.57% today. Technical indicators show mixed signals with a bearish overall trend but bullish oscillators including oversold RSI readings. The stock faces resistance at $5 and support at $4. Recent news highlights volatility with significant price gaps and volume spikes.
Outlook remains highly volatile given the leveraged structure and dependence on COIN performance. Investment opportunities exist for short-term traders capitalizing on momentum swings, but risks include amplified losses, regulatory uncertainty, and crypto market sensitivity. Long-term investors should approach with caution.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
